Annual Meeting

Arginine tango

How a bacterial enzyme enables immune evasion
Nicole Lynn
April 27, 2021
The bacteria Staphylococcus aureus, found on human skin and in the nose, is the leading pathogen among dermal and soft tissue infections. In the immunocompromised or those in hospital settings, S. aureus can cause serious infections.

As a means to evade the host immune response, S. aureus uses an enzyme called oleate hydratase, or OhyA, to inactivate antimicrobial unsaturated fatty acids in the membrane that would otherwise inhibit bacterial growth. Research scientists at St. Jude Children’s Research Hospital reported today the structure and catalytic mechanism of OhyA.

Christopher Radka of St. Jude’s Department of Infectious Diseases describes the research during a presentation Tuesday at 2 p.m. EDT at the 2021 ASBMB Annual Meeting, held in conjunction with the Experimental Biology conference.

Radka and colleagues used X-ray crystallography to determine the structure of OhyA. Solving and evaluating multiple OhyA crystal structures highlighted a coordinated dance that occurs between key arginine residues and the unsaturated fatty acid substrate in the active site of the enzyme, a process facilitated by the nucleotide cofactor FAD.
Radka et al. JBC 2021
The 18:1 fatty acid substrate (black) first encounters Arg81 of OhyA, which blocks the entrance to the active site until FAD binds. Upon FAD (cyan) binding, Arg81 rotates, allowing the substrate into the active site. Arg81 continually rotates the substrate in the active site, allowing for inactivation of the antimicrobial fatty acid substrate to hydroxy fatty acid, or h18:0. After catalysis, Arg78 lunges to expel h18:0 from the active site.

In this dance, the substrate is first guided into the binding tunnel by the oleate carbonyl of OhyA, then encounters its first arginine dance partner (Arg81) at the entrance of the active site. FAD binding then triggers the rotation of Arg81 that guides the fatty acid as it curls into the active site. After catalysis, a second arginine (Arg78) rotates behind the fatty acid carboxyl to release the hydroxylated product from the active site.
“What’s novel about the (active site) is how these conserved arginines guide the substrate through the donut-shaped active site,” Radka said. “Here, the arginines dance like two partners in a tango.”

This highly choreographed dance controls how the fatty acid substrate moves into and out of the active site. “In this coordinated tango at the active site, the FAD is the dramatic third character whose role is to come in and advance the dance so the chemistry can occur,” Radka said.

In this reaction, FAD remains oxidized and unconsumed. This quality is advantageous for industrial biotechnology research looking to use OhyA; FAD-dependent reactions often consume FADH2 and require continued starting product, which can be costly.

Future goals for this research include determining the structural elements required for S. aureus OhyA to remove antimicrobial fatty acids from the membrane.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Nicole Lynn

Nicole Lynn holds a Ph.D. from UCLA and is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Discoveries made possible by DNA
Feature

Discoveries made possible by DNA

Nov. 24, 2025

The discovery of DNA’s double helix revealed how genetic information is stored, copied and expressed. Revisit that breakthrough and traces how it laid the foundation for modern molecular biology, genomics and biotechnology.

Unraveling the language of histones
Profile

Unraveling the language of histones

Nov. 20, 2025

Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.

How Alixorexton could transform narcolepsy treatment
News

How Alixorexton could transform narcolepsy treatment

Nov. 18, 2025

A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.

Phosphatases and pupils: A dual legacy
Profile

Phosphatases and pupils: A dual legacy

Nov. 13, 2025

Yale professor Anton Bennett explores how protein tyrosine phosphatases shape disease, while building a legacy of mentorship that expands opportunity and fuels discovery in biochemistry and molecular biology.

Extracellular vesicles offer clues to cattle reproduction
Journal News

Extracellular vesicles offer clues to cattle reproduction

Nov. 11, 2025

Extracellular vesicles from pregnant cattle support embryo development better than laboratory models, highlighting their potential to improve reproductive efficiency in bovine embryo cultures. Read more about this recent MCP paper.

Proteomics reveals protein shifts in diabetic eye disease
Journal News

Proteomics reveals protein shifts in diabetic eye disease

Nov. 11, 2025

Using proteomics, researchers identified protein changes in eye fluid that mark diabetic retinopathy progression and may serve as biomarkers for vision-threatening complications. Read more about this recent MCP paper.